Daniel George, MD

Closed portfolio with an early-phase archive tilt

According to ClinicalTrials.gov-derived indexes, Daniel George, MD sits in the upper quartile of US sponsors by registered trial count (#2,085 of 15,742 sponsors by registered trial count).

6 total trials none currently recruiting 5 completed early-phase tilt upper quartile by trial count

Daniel George, MD: 6 sponsored US clinical trials, none currently recruiting.

Daniel George, MD sponsors 6 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 5 completed. 0 of these trials are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Hormone-refractory Prostate Cancer, with 1 trials.

Upper-quartile sponsor footprint

Daniel George, MD sits in the upper quartile of the sponsor corpus (#2,085 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.

Indexed trials (enrollment closed)

6 total, page 1 of 1

TERMINATED Phase 1

A Phase Ib Study of Intravenous Copper Loading With Oral Disulfiram in Metastatic, Castration Resistant Prostate Cancer

NCT02963051
COMPLETED Phase 2

Apalutamide and Abiraterone Acetate in African American and Caucasian Men With Metastatic Castrate Resistant Prostate Cancer

NCT03098836
COMPLETED Phase 1

Pazopanib, Docetaxel, Prednisone Prostate

NCT01385228
COMPLETED Phase 1

A Phase Ib Study of Rad001 and Sutent to Treat Renal Cell Carcinoma

NCT00788060
COMPLETED Phase 2

RAD001 in Patients With Metastatic, Hormone-Refractory Prostate Cancer

NCT00629525
COMPLETED Phase 1

Vatalanib and Everolimus in Treating Patients With Advanced Solid Tumors

NCT00303732

Phase Distribution

PhaseTrial count
Phase 1 4
Phase 2 2

Therapeutic Areas

Hormone-refractory Prostate Cancer 1
Renal Cell Carcinoma 1

How the Daniel George, MD early-phase archive is shaped

6 indexed studies, none listed as recruiting (0% open); 5 completed (83%).

Phase mix: 0 late (III/IV) vs 6 early (I/II) (early-phase heavy).

Top condition: Hormone-refractory Prostate Cancer (1 trial), 1 other listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Daniel George, MD: archived-pipeline peers nationwide

Peers matched on 6 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Daniel George, MD sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%20%40%60%80% Total trials Recruiting share Daniel George, MD23andMeAardvark TherapeuticsAbbisko Therapeutics CoAbGenomics B.V Taiwan Branch10xBio22nd Century Group3-C Institute for Social Development3 Waves Wellness
Daniel George, MD sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Daniel George, MD sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 6 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Daniel George, MD page

6 registered trials is a research-attention snapshot, not an endorsement of Daniel George, MD or any single study.

  • None of Daniel George, MD's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Hormone-refractory Prostate Cancer is the condition Daniel George, MD studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Hormone-refractory Prostate Cancer trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Daniel George, MD pipeline card: 6 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.